Table 3.
Baseline mean scores (SD) by treatment arm
| EORTC-QLQ C30 |
CR |
TT |
|---|---|---|
| (n=62) | (n=59) | |
| physical functioning |
84,1 (18,7) |
83,2 (16,0) |
| role functioning |
70,2 (27,4) |
66,4 (29,3) |
| cognitive functioning |
86,0 (20,5) |
82,8 (22,3) |
| emotional functioning |
78,8 (18,1) |
74,4 (20,0) |
| social functioning |
80,6 (22,6) |
82,2 (19,8) |
| fatigue |
29,7 (20,7) |
35,0 (24,9) |
| nausea & vomiting |
7,5 (19,0) |
5,1 (15,2) |
| pain |
24,7 (24,7) |
24,5 (24,4) |
| global health status |
69,0 (21,7) |
67,2 (17,5) |
| dyspnea |
11,3 (22,5) |
15,3 (26,5) |
| insomnia |
26,9 (28,2) |
35,0 (29,3) |
| loss of appetite |
12,9 (27,2) |
10,2 (18,8) |
| obstipation |
12,4 (25,8) |
11,3 (18,2) |
| diarrhea |
6,5 (16,9) |
4,0 (12,5) |
| financial difficulty |
9,7 (24,4) |
13,0 (24,8) |
|
EORTC-QLQ BR23 |
CR |
TT |
|
(n=62) |
(n=59) |
|
| systemic treatment side effects |
13,9 (14,2) |
15,4 (16,0) |
| body image |
73,7 (28,6) |
73,0 (30,9) |
| future perspective |
52,7 (29,9) |
54,2 (29,0) |
| arm symptoms |
23,8 (22,6) |
24,9 (21,6) |
| breast symptoms |
21,9 (18,6) |
19,9 (16,6) |
| |
CR (n=8) |
TT (n=13) |
| upset by hair loss |
33,3 (35,6) |
35,9 (39,6) |
| |
CR (n=56) |
TT (n=54) |
| sexual functioning |
22,3 (23,2 |
25,0 (23,3) |
| |
CR (n=28) |
TT (n=33) |
| sexual enjoyment | 56,0 (28,8) | 55,6 (28,5) |